Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Drug

AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA

Fineline Cube Sep 29, 2024

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...

Company Deals

Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development

Fineline Cube Sep 29, 2024

Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has...

Company

HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility

Fineline Cube Sep 29, 2024

HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province,...

Company Deals

Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation

Fineline Cube Sep 29, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...

Company Drug

Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company

3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline

Fineline Cube Sep 29, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...

Policy / Regulatory

China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions

Fineline Cube Sep 29, 2024

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Policy / Regulatory

China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel

Fineline Cube Sep 29, 2024

The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...

Company Deals

OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor

Fineline Cube Sep 28, 2024

Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution...

Company Drug

Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...

Company Drug

AstraZeneca’s Tagrisso Secures FDA Approval for Unresectable Stage III EGFRm NSCLC

Fineline Cube Sep 27, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN), a UK-based pharmaceutical giant, has announced that it has received...

Company Deals

Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of...

Company Deals

Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation

Fineline Cube Sep 27, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into...

Company Deals

FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism

Fineline Cube Sep 27, 2024

The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...

Policy / Regulatory

Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024

Fineline Cube Sep 27, 2024

The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...

Company Deals

Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA

Fineline Cube Sep 27, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company

China’s Pharmaceutical Industry Sees Mixed Results in H1 2024, CAPEM Data Reveals

Fineline Cube Sep 27, 2024

The China Association of Pharmaceutical Enterprises Management (CAPEM) has released a comprehensive set of data...

Policy / Regulatory

Shanghai Medical Procurement Platform Sets Price Cap for Non-Locally Supplied Drugs

Fineline Cube Sep 27, 2024

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) has issued a notification concerning the online procurement prices...

Company Deals

Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China

Fineline Cube Sep 27, 2024

Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S.,...

Posts pagination

1 … 336 337 338 … 711

Recent updates

  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
  • Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321
  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.